Please assess the completion status of the following clinical trial:

Trial Title: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of rheumatoid arthritis~* Non-respondent or intolerant to non-biologic disease-modifying anti-rheumatic drug (DMARD) therapy~* Patient has been prescribed a first biologic therapy up to 6 weeks prior to the inclusion visit, irrespective of the treatment prescribed~Exclusion Criteria:~* Patients whose first biologic therapy is given as part of a clinical trial studying rheumatoid arthritis (RA) treatment~* Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months~* Patients whose first biologic is rituximab, abatacept or anakinra.~* Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).